• 1
    Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;314:1801.
  • 2
    Mackenzie R, Klistorner A. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;314:1693.
  • 3
    Wilson EA, Brodie MJ. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;314:1693.
  • 4
    Wong IC, Mawer GE, Kelly G. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;314:1693.
  • 5
    Blackwell N, Hayllar J, Kelly G. Patients taking vigabatrin should have regular visual field testing. Br Med J 1997;314:1693.
  • 6
    Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction. Neurology 1998;50:6148.
  • 7
    Ruether K, Pung T, Kellner U, Schmitz B, Hartmann M, Seeliger M. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 1998;116:8179.
  • 8
    Harding GFA, Wild JM, Robertson K, Edson A, Barber C, Lawden MC, Betts TA. Electroculography, ERGs, multifocal ERGs and VEPs in epileptic patients showing visual field disorders. Electro-encephalogr Clin Electrophysiol 1997;103:96.
  • 9
    Kalviainen R, Nousiainen I, Nikoskelainen E, et al. Visual field defects associated with initial vigabatrin monotherapy as compared with initial carbamazepine therapy. Epilepsia 1998;39(suppl 2):5.
  • 10
    Rao GP, Fat FA, Kyle G, Leach JP, Chadwick DW, Batterbury M. Study is needed of visual field loss associated with any long term antiepileptic drug. Br Med J 1998;317:206.
  • 11
    Kalviainen R, Nousiainen I, Mantyjarvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999;53:9226.
  • 12
    Lawden MC, Eke T, Degg C, Harding GFA, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry (In press).
  • 13
    Keitner JL, Johnson CA, Beck RW, et al. Quality control functions of the visual field reading centre (VFRC) for the optic neuritis treatment trial (ONTT). Control Clin Trials 1993;14:14359.
  • 14
    Greve EL. Single and multiple stimulus static perimetry in glaucoma: the two phases of perimetry. Doc Ophthalmol 1973;36:(suppl):1267.
  • 15
    Anderson DR. Testing the field of vision. St. Louis : Mosby, 1982:469.
  • 16
    Heijl A, Lindgren G, Olsson J. Normal variability of static perimetric threshold values across the central visual field. Arch Ophthalmol 1987;105:15449.
  • 17
    Heijl A, Lindgren G, Olsson J. A package for the statistical analysis of visual fields. Doc Ophthalmol Proceedings Series 1987;49:593600.
  • 18
    Wild JM, Dengler-Harles M, Searle AET, O'Neill EC, Crews SJ. The influence of the learning effect on automated perimetry in patients with suspected glaucoma. Acta Ophthalmol 1989;67:53745.
  • 19
    Heijl A, Lindgren G, Olsson J. The effect of perimetric experience in normal subjects. Arch Ophthalmol 1989;107:816.
  • 20
    Szlyk JP, Fishman GA, Alexander KR, Revelins BI, Derlacki DJ, Anderson RJ. Relationship between difficulty in performing daily activities and clinical measures of visual function in patients with retinitis pigmentosa. Arch Ophthalmol 1997;115:539.
  • 21
    Mauguire F, Chauvel P, Dewailly J, Dousse N. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractive epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. Epilepsia 1997;38:3018.
  • 22
    Harding GFA, Robertson K, Edson A, Barnes P, Wild JM. Visual electrophysiological effect of GABA transaminase blocker. Doc Ophthalmol (In press).
  • 23
    Harding GFA, Jones LA, Tipper VJ, Betts TA, Mumford JP. Electroretinogram, pattern electroretinogram and visually evoked potential assessment in patients receiving vigabatrin. Epilepsia 1995;36:S108.
  • 24
    Algvere P, Westbeck S. Human electroretinogram in response to double flashes of light during the course of dark adaptation. Vision Res 1978;12:195214.
  • 25
    Kline RP, Ripps H, Dowling JE. Generation of b-wave currents in the skate retina. Proc Nat Acad Sci USA 1978;75:5727.
  • 26
    Neal MJ, Shah MA. Development of tolerance to the effects of vigabatrin (γ-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina. Br J Pharmacol 1990;100:3248.
  • 27
    Cubells JF, Blanchard JS, Smith DM, Makman MH. In vivo action of enzyme-activated irreversible inhibitors of glutamic acid decarboxylase and γ-aminobutyric acid transaminase in retina vs brain. J Pharmacol Exp Ther 1986;238:50814.
  • 28
    Harding GFA. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;313:1694.
  • 29
    Beran RG, Currie J, Sandbach J, Plunkett M. Visual field restriction with new anti-epileptic medication. Epilepsia 1998;39 (suppl 2):6.